The U.S. Food and Drug Administration has approved Journavx, a new type of pain medication developed by Vertex Pharmaceuticals, marking the first significant advancement in pain treatment in over two decades. Journavx offers a non-opioid alternative for managing short-term pain, potentially addressing the ongoing opioid crisis.
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
It’s the first new pharmaceutical approach to treating pain in more than 20 years, offering an alternative to both opioids and over-the-counter medications like ibuprofen and acetaminophen. But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain.\Two studies in more than 870 patients with acute pain following foot and abdominal surgeries showed Vertex’s pill provided more relief than a dummy pill but didn’t outperform a common opioid-acetaminophen combination pill. “It’s not a slam dunk on effectiveness,” said Michael Schuh of the Mayo Clinic, a pharmacist and pain medicine expert who was not involved in the research. “But it is a slam dunk in that it’s a very different pathway and mechanism of action, so I think that shows a lot promise.”\Vertex began researching the drug in the 2000s, when drug overdoses were rocketing upward, principally driven by mass prescribing of opioid painkillers for common ailments like arthritis and back pain. Prescriptions have fallen sharply in the last decade and the current wave of the opioid epidemic is mainly due to illicit fentanyl, not pharmaceutical medicines. Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids' addictive effects. Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. 'In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Vertex’s Dr. David Altshuler, told the Associated Press last year.“The new medication has side effect profiles that are inherently, not only different, but don’t involve the risk of substance abuse and other key side effects associated with opioids,” said Dr. Charles Argoff of the Albany Medical Center, who consulted for Vertex on the drug's development. The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary condition that causes insensitivity to pain. Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally represents a bigger financial opportunity than acute pain. But the Boston drugmaker's share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs. The drug didn't perform significantly better than placebo, the research found. “We believe the data reflect a near worst-case scenario for this key pipeline program,” biotechnology analyst Brian Abrahams said in a research note to investors, adding that the results jeopardized estimates that Vertex's pipeline could be worth billions across multiple forms of pain. Still, Vertex executives said they plan to move forward with a new, late-stage study of the drug, theorizing that a different trial design could yield better results and pave the way for FDA approval in chronic pain
PAIN MANAGEMENT OPIOIDS NEW DRUG FDA APPROVAL VERTEX PHARMACEUTICALS JOURNAVX
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
FDA Approves New Nonopioid Pain Killer JournavxThe FDA has approved a new nonopioid painkiller, Journavx, for moderate to severe acute pain in adults. This could potentially reduce opioid prescriptions after surgery or provide an alternative for those who can't tolerate other pain medications.
Read more »
FDA approves new painkiller that shows promise and challenges of opioid alternativesThe U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.
Read more »
FDA approves painkiller designed to eliminate the risk of addiction associated with opioidsU.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Read more »
FDA approves painkiller designed to eliminate the risk of addiction associated with opioidsU.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Read more »